COSM

● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform ● 60.5% of U.S. online checkout orders included a subscription, rising to more than 75% in recent days as adoption accelerates ● $919,945 monthly subscription value at standard renewal pricing as of October 14, 2026 ● 2.4 product units per subscription on average, with 14,793 units across 12,408 active subscription lines ● 10,881 U.S. online checkout orders tracked by the Company's subscription management platform CHICAGO, IL / ACCESS Newswire / October 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that it has reached 6,287 active subscriptions in its U.S. online stores, substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026. Overall, 60.5% of the U.S. online checkout orders tracked by the Company's subscription management platform have included a subscription, with adoption accelerating in recent days.

Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date $902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-day period Accelerating: average daily sales of more than $60,000 over the past 10 days, double the 30-day average Approaching U.S. target: the 10-day pace, if sustained, corresponds to approximately $21.9 million annualized, nearing the over $23 million in annual U.S. revenue the Company previously projected within 12 to 18 months Platform to scale: the Company is evaluating extending the model to additional brands and markets CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that its United States direct-to-consumer sales reached a record of more than $92,000 in a single day on October 11, 2026. Sales over the past 30 days totaled $902,000, while average daily sales over the past 10 days exceeded $60,000, double the 30-day average.

More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics Proprietary brands sold in more than 40 countries - across Europe, the Middle East, North America and Asia, through pharmacies, hospitals, retail chains and e-commerce Addressable markets of approximately $946 billion - the six product categories and two service markets in which the Company competes are estimated by third-party research at approximately $946 billion in 2025, projected to reach approximately $1.76 trillion by 2033 Infection control gaining hospital and retail traction - C-Scrub listed at Tesco and Superdrug and tested under EN 12791 for surgical hand disinfection; C-Sept PRO adopted across leading Greek hospital groups; C-ScrubVet launched into animal health Gross margins of over 70% expected across key brands - including Sky Premium Life, the 18 Series, C-Scrub and C-Sept Manufactured at GMP-certified facilities on two continents - principally at Cana Laboratories' EU GMP-licensed, EMA-certified facility in Athens, and at GMP-certified, FDA-registered facilities in the United States Supported by integrated services - contract manufacturing at Cana Laboratories, pharmaceutical distribution in Greece and the United Kingdom, ZipDoctor telehealth in the United States, and AI-enabled research and development A platform for future brands - registrations, distribution partners, retail and hospital listings and manufacturing capacity already in place are expected to support further launches into existing markets at lower cost and in less time CHICAGO, IL / ACCESS Newswire / October 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an overview of its brand portfolio and the global markets it addresses. The portfolio comprises more than 15 proprietary brands and product lines and 10 branded generics across five product categories, sold in more than 40 countries through pharmacies, hospitals, retail chains and e-commerce.

Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18% Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to date Pharmacies served daily up 3.6x, from ~100 in 2017 to ~360 today, within a total network of more than 1,500 pharmacies Operating leverage from enhanced route density and optimized order execution - during 2025, revenue per customer up 12%, profitability per customer up 14% and the active customer base up 20% Robotics, automation and AI-enabled systems across procurement, inventory and order execution, with capacity that could support a further $40 million or more in annual revenue, which would provide infrastructure for annualized revenue above $100 million Instrumental to the Company's 2029 guidance of $200.6 million in revenue, $71.2 million in gross profit, $44.2 million in adjusted EBITDA and $31.0 million in net income CHICAGO, IL / ACCESS Newswire / September 29, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today provided an update on its wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A. ("CosmoFarm"), which delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized revenue run-rate of over $60 million.

Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements Gross margins of over 90% - among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with 7.7 million units added in September alone Diversified across 11 therapeutic categories, reducing dependence on any single product or partner, under multi-year agreements averaging approximately four years, with certain contracts extending up to ten years Ongoing investment program underway to take Cana to the next level of capacity and capability, as the division scales toward its target of over $10 million in recurring annual gross profit Supports the Company's 2029 guidance targets of $200.6 million in revenue and $71.2 million in gross profit, with high-margin contract manufacturing a key driver of the planned margin expansion CHICAGO, IL / ACCESS Newswire / September 28, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that the contract manufacturing ("CMO") pipeline of its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has surpassed $20 million in implied revenue over the life of the underlying agreements, representing over $18 million in implied gross profit at gross margins of over 90%, as the production pipeline reaches a record of more than 32.7 million units.

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026 Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows Division targeted to generate over $10 million in recurring annual profit at full capacity CHICAGO, IL / ACCESS Newswire / September 15, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has secured new five-year contract manufacturing agreements with Target Pharma totaling approximately 5.2 million units.

Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption Intellectual property owned outright, with patent applications advanced into the United States, Europe, Australia and Canada Addresses a global weight management market projected to reach $562.2 billion by 2033 (14.2% CAGR) - set against a broader tokenized real-world-asset market projected to reach $18.9 trillion by 2033 CHICAGO, IL / ACCESS Newswire / September 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that it has engaged Prime Ledger Inc. ("Prime Ledger"), a digital asset advisory and tokenization firm, to structure a tokenized financing backed by the Company's intellectual property in CCX0722, an ingestible hydrogel-based medical device in development for weight management.

500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio Cumulative contract manufacturing orderbook increases to more than 27.5 million units, up from over 25 million units reported in June 2026 Further strengthens recurring cash flow visibility and expands Cana's long-term manufacturing relationships with established pharmaceutical companies CHICAGO, IL / ACCESS Newswire / September 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has secured a new five-year contract manufacturing agreement with Viofar covering approximately 2.5 million units of ROSARTIA.

First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026 Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinics Certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use Manufactured in-house at Cana Laboratories' EU GMP-licensed, EMA-certified facility, consistent with the Company's vertically integrated model Extends the C-Scrub franchise beyond human healthcare, addressing the $69 billion global animal health market Expected to be one of several catalysts supporting the Company's previously issued 2029 guidance of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31 million in net income CHICAGO, IL / ACCESS Newswire / September 9, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet. C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria, fungi and enveloped viruses.

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.